The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
Valeant Pharmaceutical’s offices in Montreal.
Valeant Pharmaceutical’s offices in Montreal.
(Ryan Remiorz/The Canadian Press)

It may be Valeant's turn to face the curse of the TSX

Mike Pearson, chairman and chief executive of Valeant Pharmaceuticals Inc., has a dream: Transform his company into a top five global pharmaceutical firm through internal growth and acquisitions.

His $46-billion offer for Allergan Inc. will bring the dream closer to reality, if it succeeds. But it comes with a potential downside – Valeant will be well on its way to becoming the top-weighted stock on the S&P/TSX composite index.